<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667937</url>
  </required_header>
  <id_info>
    <org_study_id>CUCO-UV</org_study_id>
    <nct_id>NCT03667937</nct_id>
  </id_info>
  <brief_title>Effectiveness of a Hydrophobic Dressing for Microorganisms' Colonization and Infection Control of Vascular Ulcers</brief_title>
  <acronym>CUCO-UV</acronym>
  <official_title>Effectiveness of a Hydrophobic Dressing for Microorganisms' Colonization and Infection Control of Vascular Ulcers: An Open, Controlled, Randomized Study, With Blinded Endpoint (PROBE Trial): CUCO-UV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaga</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BSN Medical GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andalusian Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Malaga</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of CUTIMED® hydrophobic dressings against
      AQUACEL® silver dressings in bacterial colonization of vascular ulcers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic wounds with torpid evolution are a real challenge for health services today. In the
      case of venous ulcers, it is estimated that more than 80% of these wounds may be colonized or
      infected by bacteria, which is associated with its chronification by delaying the healing
      process.

      The most widespread therapeutic strategy in routine clinical practice is the use of silver
      dressings, due to its high antimicrobial power, although the effectiveness of these in venous
      ulcers is not supported by solid evidence. In addition, there are some uncertainties about
      the possible adverse effects of systemic absorption of silver molecules, as well as bacterial
      resistance to silver and the high cost associated with prolonged treatments.

      In this sense, a novel method to deal with this problem is the use of dressings with high
      hydrophobic power, such as CUTIMED®.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microorganisms' Colonization Level</measure>
    <time_frame>Change from baseline, at 4, 8 and 12 weeks</time_frame>
    <description>Evaluated by Reverse Transcription Polymerase Chain Reaction (RT-PCR) identification technique and quantified in colony forming units (CFU) and in ng of bacterial DNA per μL of vascular ulcer exudate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain due to the wound</measure>
    <time_frame>Change from baseline at 4, 8 and 12 weeks</time_frame>
    <description>Measured with tha Visual Analogue Scale (VAS): Minimum score=1; Maximum score=10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound size (wound reduction percentage)</measure>
    <time_frame>Baseline, 4, 8 and 12 weeks</time_frame>
    <description>It will be evaluated by planimetry with PictZar 7.5 software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing time</measure>
    <time_frame>Change from baseline at 4, 8 and 12 weeks</time_frame>
    <description>This outcome will be measure by number of days until healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete wound healing (Resvech 2.0 score)</measure>
    <time_frame>Change from baseline at 4, 8 and 12 weeks</time_frame>
    <description>Complete healing will be considered with a 0 score in the fourth dimension of the Resvech 2.0 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>Measured with Charing Cross Venous Ulcer Questionnaire (CCVUQ), in its Spanish version. The CCVUQ is composed of 22 items that determine four important dimensions for health: the social function, domestic activities, the aesthetic dimension and the emotional state. Each item should be assessed using a Likert scale with a punctuation from 1 to 5. In their interpretation, lower scores indicate a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Change from baseline at 4, 8 and 12 weeks</time_frame>
    <description>Adverse events related with the treatment, referred by patients, caregivers or health professionals</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Wound healing evolution</measure>
    <time_frame>Baseline, 4, 8 and 12 weeks</time_frame>
    <description>Measured with &quot;Resultados esperados de la valoración y evolución de la cicatrización de las heridas crónicas&quot; (Expected results of chronic wound healing assessment and evolution), RESVECH 2.0 scale. The punctuation varies forn 0 to 35, with 6 subscales: Wound size, Depth/affected tissues, Borders, Type of tissue in the wound bed, Type of exudate and Infection/inflammation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <condition>Bacterial Infections</condition>
  <condition>Chronic Ulcer of Skin of Lower Limb Nos</condition>
  <arm_group>
    <arm_group_label>CUTIMED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply the CUTIMED dressing. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.
If the wound exudate decreases, or the removal of the dressing is difficult, it will be changed to CUTIMED gel; in case of abundant exudate, the use of alginate without silver will be allowed for the treatment, because it is neutral with the bacterial load, placed on the CUTIMED dressing.
Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AQUACEL silver</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply Aquacel-Ag. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.
Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CUTIMED</intervention_name>
    <description>Hydrophobic Dressing</description>
    <arm_group_label>CUTIMED</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AQUACEL silver</intervention_name>
    <description>Silver Dressing</description>
    <arm_group_label>AQUACEL silver</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patients with chronic venous vascular ulcer located in lower limbs with signs of
        critical colonization, according to the criteria of Lazareth and Moore, which imply the
        presence of at least 3 of the following five:

          1. Severe pain during dressing change

          2. Perilesional edema.

          3. Local edema.

          4. Unpleasant smell.

          5. Abundant pus

          6. Microbial colonization higher than 100000 CFUs

        Exclusion Criteria:

          -  Patients younger than 18 years old.

          -  Venous ulcer with signs of infection which requires antibiotic therapy

          -  Venous ulcers that do not meet Lazareth and Moore criteria

          -  Arterial ulcers.

          -  Patients with type I or type II diabetes.

          -  Patients with immunosuppression of any etiology or in immunosuppressive treatment or
             with NSAIDs.

          -  Patients with rheumatoid arthritis in the acute phase.

          -  Patients with dermatitis prior to the appearance of the ulcer.

          -  Patients with neuropathy or lack of sensitivity of any etiology.

          -  Patients who, for local or systemic clinical reasons, will need to initiate antibiotic
             therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Miguel Morales Asencio, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Malaga</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>José Miguel Morales Asencio, PhD</last_name>
    <phone>0034951952833</phone>
    <email>jmmasen@uma.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Carlos Morilla Herrera, PhD</last_name>
    <email>jc.morilla.sspa@juntadeandalucía.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Miguel Morales Asencio, PhD</last_name>
      <phone>0034951952833</phone>
      <email>jmmasen@uma.es</email>
    </contact>
    <investigator>
      <last_name>José Miguel Morales Asencio, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Carlos Morilla Herrera, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia García Mayor, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inmaculada Lupiáñez Pérez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José María García Cabello, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Caro Bautista, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca Villa Estrada, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfonso García Guerrero, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hilaria Vico Quintana, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Díez de los Ríos, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva María Pérez Madrigal, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Lourdes Ruiz España, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yolanda Pérez Espinosa, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yolanda Rey Becerra, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Carmen García Santamarina, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Eugenia Valdés Planes, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Carpena Del Pino, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Concepción Almoguera Gaviño, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Zaragoza Baquero, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonia María Santana Bra, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mercedes Muñoz Conde, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Javier García Díaz, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael Cabello Jaime, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Concepción Venegas Ariza, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Del Carmen Expósito Alvarez, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Begoña Martín Muñoz, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Carlos Toribio Montero, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Aranda Gallardo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Belén Moya Suárez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>González de la Torre H, Quintana-Lorenzo ML, Perdomo-Pérez E, Verdú J. Correlation between health-related quality of life and venous leg ulcer's severity and characteristics: a cross-sectional study. Int Wound J. 2017 Apr;14(2):360-368. doi: 10.1111/iwj.12610. Epub 2016 Apr 25.</citation>
    <PMID>27112627</PMID>
  </reference>
  <reference>
    <citation>Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992 Aug;1(2):113-9.</citation>
    <PMID>1366259</PMID>
  </reference>
  <reference>
    <citation>Lazareth I, Ourabah Z, Senet P, Cartier H, Sauvadet A, Bohbot S. Evaluation of a new silver foam dressing in patients with critically colonised venous leg ulcers. J Wound Care. 2007 Mar;16(3):129-32.</citation>
    <PMID>17385590</PMID>
  </reference>
  <reference>
    <citation>Moore K, Hall V, Paull A, Morris T, Brown S, McCulloch D, Richardson MC, Harding KG. Surface bacteriology of venous leg ulcers and healing outcome. J Clin Pathol. 2010 Sep;63(9):830-4. doi: 10.1136/jcp.2010.077032. Epub 2010 Jul 29.</citation>
    <PMID>20671048</PMID>
  </reference>
  <reference>
    <citation>Moore MF. Prospective, Descriptive Study of Critically Colonized Venous Leg Ulcers Managed With Silver Containing Absorbent Dressings and Compression. J Am Coll Clin Wound Spec. 2014 Sep 16;5(2):36-9. doi: 10.1016/j.jccw.2014.08.002. eCollection 2013 Aug.</citation>
    <PMID>26199888</PMID>
  </reference>
  <reference>
    <citation>Pugliese DJ. Infection in Venous Leg Ulcers: Considerations for Optimal Management in the Elderly. Drugs Aging. 2016 Feb;33(2):87-96. doi: 10.1007/s40266-016-0343-8. Review.</citation>
    <PMID>26833351</PMID>
  </reference>
  <reference>
    <citation>Totty JP, Bua N, Smith GE, Harwood AE, Carradice D, Wallace T, Chetter IC. Dialkylcarbamoyl chloride (DACC)-coated dressings in the management and prevention of wound infection: a systematic review. J Wound Care. 2017 Mar 2;26(3):107-114. doi: 10.12968/jowc.2017.26.3.107. Review.</citation>
    <PMID>28277989</PMID>
  </reference>
  <reference>
    <citation>Wendelken ME, Berg WT, Lichtenstein P, Markowitz L, Comfort C, Alvarez OM. ﻿﻿﻿﻿﻿﻿﻿Wounds measured from digital photographs using photodigital planimetry software: validation and rater reliability. Wounds. 2011 Sep;23(9):267-75.</citation>
    <PMID>25879267</PMID>
  </reference>
  <reference>
    <citation>González-Consuegra, R.V., Verdú, J., 2010. Proceso de adaptación al castellano del Charing Cross Venous Ulcer Questionnaire (CCVUQ) para medir la calidad de vida relacionada con la salud en pacientes con úlceras venosas. Gerokomos 21, 80-87</citation>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Malaga</investigator_affiliation>
    <investigator_full_name>JOSE MIGUEL MORALES ASENCIO</investigator_full_name>
    <investigator_title>Head of the Department of Nursing. Professor of Research and Evidence Based Health Care</investigator_title>
  </responsible_party>
  <keyword>Venous Ulcer</keyword>
  <keyword>Leg Injuries</keyword>
  <keyword>Bacterial Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

